Machens Andreas, Dralle Henning
Department of General, Visceral and Vascular Surgery, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Str. 40, D-06097, Halle/Saale, Germany.
World J Surg. 2007 May;31(5):957-68. doi: 10.1007/s00268-006-0769-y.
Since DNA tests have enabled reliable identification of asymptomatic RET (rearranged during transfection) gene carriers, myriads of publications have appeared on genotype-phenotype relationships. A comprehensive appraisal of this body of evidence using evidence-based methodology is pending.
This study was based on systematic evaluation of the literature using evidence-based criteria.
(1) There is a distinct age-related progression of hereditary medullary thyroid carcinoma (MTC) in carriers of RET mutations (grade C). (2) Among the high-risk RET mutations, those in codon 634 cause higher penetrance rates of the multiple endocrine neoplasia 2A phenotype (MTC, pheochromocytoma, and parathyroid hyperplasia/adenoma) than mutations in codons 609, 611, 618, and 620, irrespective of the amino acid substituting for cysteine (grade C). (3) DNA-based screening is superior to calcitonin-based screening in asymptomatic RET carriers (grade C). (4) Using a worst-case scenario, i.e., considering the earliest finding of MTC in asymptomatic RET carriers, pre-emptive thyroidectomy should be performed before that time (grade C) to be truly prophylactic. Specifically, for carriers of highest-risk mutations (codon 918): within the first year of life; for carriers of high-risk mutations (codon 609, 611, 618, 620, 630, and 634): before the age of 5 years; and for carriers of least-high risk mutations (codon 768, 790, 791, 804, and 891): before the age of 5-10 years. Strict adherence to these grade C recommendations can result in undertreatment of the former (codon 634) and overtreatment of the latter.
These genotype-phenotype correlations provide a solid foundation on which to base surgical concepts, leaving little room for randomized controlled clinical trials.
由于DNA检测能够可靠地识别无症状的RET(转染期间重排)基因携带者,关于基因型-表型关系的出版物大量涌现。使用循证方法对这一证据体系进行全面评估仍有待进行。
本研究基于使用循证标准对文献进行系统评价。
(1)RET突变携带者的遗传性甲状腺髓样癌(MTC)存在明显的年龄相关进展(C级)。(2)在高危RET突变中,密码子634处的突变导致多内分泌腺瘤2A型表型(MTC、嗜铬细胞瘤和甲状旁腺增生/腺瘤)的外显率高于密码子609、611、618和620处的突变,无论取代半胱氨酸的氨基酸是什么(C级)。(3)对于无症状的RET携带者,基于DNA的筛查优于基于降钙素的筛查(C级)。(4)采用最坏情况设想,即考虑无症状RET携带者中MTC的最早发现时间,应在该时间之前进行预防性甲状腺切除术(C级)才能真正起到预防作用。具体而言,对于最高危突变(密码子918)携带者:在1岁以内;对于高危突变(密码子609、611、618、620、630和634)携带者:在5岁之前;对于低高危突变(密码子768、790、791、804和891)携带者:在5至10岁之前。严格遵循这些C级建议可能导致对前者(密码子634)治疗不足,而对后者治疗过度。
这些基因型-表型相关性为手术理念提供了坚实基础,使得随机对照临床试验的空间很小。